Growth hormone-releasing peptides

European Journal of Endocrinology

Volumn 136, Issue 5, 1997, Pages 445-460

  Ghigo, E ^a,c   Arvat, E ^a   Muccioli, G ^b   Camanni, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; L 700653; UNCLASSIFIED DRUG;

DESENSITIZATION; DRUG EFFECT; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOTHYROIDISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR AFFINITY; REVIEW; SEQUENCE HOMOLOGY; SHORT STATURE;

EID: 0030998227     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1360445     Document Type: Review

References (183)

1. Bowers CY, Chang J, Momany F & Folkers K. Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In Molecular Endocrinology, pp 287-292. Ed I Macintyne. Amsterdam: Elsevier/North Holland Biochemical Press, 1977.
2. Bowers CY, Momany F, Reynolds GA & Hong A. A study on the regulation of growth hormone release from the pituitaries of rats in vitro. Endocrinology 1981 108 1071-1080.
3. Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A & Newlander K. Design, synthesis and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981 108 31-59.
4. Bowers CY, Momany FA, Reynolds GA & Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984 114 1537-1545.
5. Momany FA, Bowers CY, Reynolds GA, Hong A & Newlander K. Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 1984 114 1531-1536.
6. Badger TM, Millard WY, McCormick GF, Bowers CY & Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984 115 1432-1438.
7. 2 in rat primary pituitary cell monolayer culture. Endocrinology 1985 116 952-957.
8. McCormick GF, Millard WJ, Badger TN, Bowers CY & Martin JB. Dose-response characteristics of various peptides with growth hormone-releasing activity in the unanesthetized male rat. Endocrinology 1985 117 97-105.
9. Malozowski S, Hao EN, Ren SG, Marin G, Liu L, Southers JL & Merriam GR. Growth hormone (GH) responses to the hexapeptide GH-releasing peptide and GH-releasing hormone (GHRH) in the cynomologus macaque: evidence for non-GHRH-mediated responses. Journal of Clinical Endocrinology and Metabolism 1991 73 314-317.
10. Kraft LA, Baker PK, Doscher ME & Ricks CA. Effect of a syntheticgrowth hormone releasing hexapeptide on serum growth hormone levels in steers. Journal of Animal Science 1984 59 (Suppl) 218.
11. Doscher ME, Baker PK, Kraft LA & Ricks CA. Effect of a synthetic growth hormone releasing hexapeptide (BI 679) and growth hormone releasing factor (GRF) on serum growth hormone levels in barrows. Journal of Animal Science 1984 59 (Suppl) 218.
12. Deghenghi R, Cananzi M, Torsello A, Battisti C, Muller EE & Locatelli V. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences 1994 54 1321-1328.
13. Ilson BE, Jorkasky DK, Curnow RT & Stote RM. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. Journal of Clinical Endocrinology and Metabolism 1989 69 212-214.
14. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS & Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism 1990 70 975-982.
15. 2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men. Endocrinologia Japonica 1991 38 15-21.
16. Bowers CY, Alster DK & Frentz JM. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. Journal of Clinical Endocrinology and Metabolism 1992 74 292-298.
17. Hartman ML, Farello G, Pezzoli SS & Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. Journal of Clinical Endocrinology and Metabolism 1992 74 1578-1384.
18. Bowers CY. GH releasing peptides. Structure and kinetics. Journal of Pediatrics and Endocrinology 1993 6 21-31.
19. Penalva A, Carballo A, Pombo M, Casanueva FF & Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH). atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. Journal of Clinical Endocrinology and Metabolism 1993 76 168-171.
20. Bowers CY, Veeraragavan K & Sethumadhavan K. Atypical growth hormone releasing peptides. In Growth Hormone II. Basic and Clinical Aspects, pp 205-222. Eds BB Bercu & RF Walker. New York: Springer-Verlag, 1993.
21. Chihara K, Kaji H, Hayashi S, Yagi H, Takeshima Y, Mitani et al. Growth hormone releasing hexapeptide: basic research and clinical application. In Growth Hormone II. Basic and Clinical Aspects, pp 223-230. Eds BB Bercu & RF Walker. New York: Springer-Verlag. 1993.
22. Deghenghi R. Growth hormone releasing peptides. In Growth Hormone Secretagogues, pp 85-102. Eds B Bercu & R Walker. New York: Serono Symposia. 1993.
23. Deghenghi R, Boutignon F, Luoni M, Grilli R, Guidi M & Locatelli V. Small peptides as potent releasers of growth hormone, Journal of Pediatric Endocrinology and Metabolism 1995 8 311-313.
24. Korbonits M & Grossman AB. Growth hormone-releasing peptide and its analogs. Novel stimuli to growth hormone release. Trends in Endocrinology and Metabolism 1995 6 43-49.
25. Laron Z. Growth hormone secretagogues. Drugs 1995 50 545-601.
26. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP et al. Aging and GH-releasing peptides. In Growth Hormone Secretagogues, pp 415-431. Eds B Bercu & R Walker. New York: Serono Symposia, 1996.
27. Smith RG, Cheng K, Pong SS, Hickey G, Jacks T, Butler B et al. A non-peptidyl GH secretagogue. Science 1993 260 1640-1643.
28. Cheng K, Chan WWS, Butler B, Wei L & Smith RG. A novel non-peptidyl growth hormone secretagogue. Hormone Research 1993 49 109-115.
29. Jacks T, Hickey G, Judith F, Taylor J, Chen II, Krupa D et al. Effects of acute and repeated intravenous administration of L-692, 585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. Journal of Endocrinology 1994 143 399-406.
30. Hickey GJ, Jacks T, Judith F, Taylor J, Schoen WR, Krupa D et al. Efficacy and specificity of L-692,429, a novel non-peptidyl growth hormone secretagogue, in beagles. Endocrinology 1994 134 695-701.
31. Chang CH, Rickes EL, Marsilio F, McGuire L, Cosgrove S, Taylor J et al. Activity of a novel non-peptidyl GH secretagogue, L-700,653, in swine. Endocrinology 1995 136 1065-1071.
32. Patchett AA, Nargunt RP, Tata JR, Chen MH, Barakat KJ, Johnston DBR et al. Design and biological activities of L-163,191 (MK-0677): a potent orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the USA 1995 92 7001-7005.
33. DeVita RJ & Wyratt MJ. Benzolactam growth hormone secretagogues. Drugs of the Future 1996 21 273-281.
34. Clark RG, Mortenesen DL, Won WB, Ma YH, Stanley MS, Somers TC, Fairhall KM, Thomas GB & Robinson ICAF. Novel GHRP analogs acutely activate the HPA axis and are diabetogenic in ZDF rats. 10th International Congress of Endocrinology. San Francisco 1996, p 282 Abstract P1-591.
35. Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H et al. MK-677, a potent novel, orally-active growth hormone (GH) secretagogue: GH, insulin-like growth factor-I and other hormonal responses in beagles. Endocrinology 1996 137 5284-5289.
36. Hickey GJ, Jacks T, Schleim K, Frazier E, Chen H, Krupa D et al. Repeated administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels. 10th International Congress of Endocrinology. San Francisco 1996, p 285 Abstract P1-604.
37. Gertz BJ, Barrett JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR et al. Growth hormone response in man to L-692,429, a novel non-peptide mimic of growth hormone-releasing peptide-6. Journal of Clinical Endocrinology and Metabolism 1993 77 1393-1397.
38. Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoll SS, Wittreich M et al. Neuroendocrine responses to a novel growth hormone secretagogue. L-692,429, in healthy older subjects. Journal of Clinical Endocrinology and Metabolism 1994 79 943-944.
39. Copinschi G, van Onderbergen A, L'hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO & van Cauter E. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-h GH profiles. Insulin-like growth factor I and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism 1996 81 2776-2782.
40. Chapman IM, Bach MA, van Cauter E, Farmer M, Krupa D, Taylor AM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism 1996 81 4249-4257.
41. Chapman IM, Hartman ML, Pezzoli SS & Thorner MO. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic. L-692,429, in older adults - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 2874-2880.
42. McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS et al. Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Biochemistry 1995 92 11165-11169.
43. Elias KA, Ingle GS, Burnier JP, Hammonds RG, McDowell RS, Rawson TE et al. In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 1995 136 5694-5699.
44. Deghenghi R, Boutignon F, Luoni F, Grilli R, Guidi M & Locatelli V. Characterization of the activity of new growth hormone secretagogues in the infant rat. 10th International Congress of Endocrinology. San Francisco 1996, p 280 Abstract P1-581.
45. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996 273 974-977.
46. Codd EE, Shu AYL & Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989 28 1139-1144.
47. Sethumadhavan K, Veeraragavan K & Bowers CY. Demonstration and characterization of the specific binding of growth hormone-releasing peptide to rat anterior pituitary and hypothalamic membranes. Biochemical and Biophysical Research Communications 1991 178 31-37.
48. Veeraragavan K, Sethumadhavan K & Bowers CY. Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes. Life Sciences 1992 50 1149-1155.
49. Pong SS, Chaung LYP, Dean DC, Nargunt RP, Patchett AA & Smith RG. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Molecular Endocrinology 1996 10 57-61.
50. Muccioli G, Ghe' C, Ghigo MC, Arvat E, Papotti M, Boghen MF et al. Presence of specific receptors for Hexarelin, a GH releasing hexapeptide, in human brain and pituitary gland. International Symposium on Growth Factors in Endocrinology and Metabolism. Berlin 1995, p 110 (Abstract).
51. Muccioli G, Ghe' C, Ghigo MC, Arvat E, Papotti M, Boghen MF et al. Growth hormone-releasing peptide receptors in human brain and pituitary gland. Fundamental Clinical Pharmacology 1996 10 (Suppl) 205.
52. Bowers CY, Sartor AO, Reynolds GA & Badger TM. On the action of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991 128 2027-2035.
53. 2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′.5′-monophosphate accumulation in rat primary cell culture. Endocrinology 1989 124 2791-2798.
54. Goth MI, Lyons CE, Canny BY & Thorner MO. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992 130 939-944.
55. 2 stimulate GH release through different receptor sites. Journal of Endocrinology 1991 129 11-19.
56. 2 (GHRP-6)-induced GH secretion in the rat. Neuroendocrinology 1992 57 247-251.
57. Clark RG, Carisson MS, Trojnar J & Robinson ICAF. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. Journal of Neuroendocrinology 1989 1 252-255.
58. Guillame V, Magnan E, Cataldi M, Dutour A, Sauze N, Renard M et al. Growth hormone (GHI)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptidc in sheep. Endocrinology 1994 135 1073-1076.
59. Dickson SL, Leng G, Dyball REJ & Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology 1995 61 36-13.
60. Conley LK, Teik JA, Deghenghi R, Imbimbo BP, Giustina A, Locatelli V et al. Mechanism of action of Hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology 1995 61 44-50.
61. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R et al. Modulation of growth hormone-releasing activity of Hexarelin in man. Neuroendocrinology 1995 61 51-56.
62. Maccario M, Arval E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP et al. Metabolic modulation of the growth hormone-releasing activity of Hexarelin in man. Metabolism 1995 44 134-138.
63. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C & Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamo-pituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. Journal of Clinical Endocrinology and Metabolism 1995 80 942-947.
64. Locke W, Kirgis HD, Bowers CY & Abdo AA. Intracerebroventricular growth hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sciences 1995 56 1347-1352.
65. Sirinathsinghji DJS, Chen HY, Hopkins R, Trumbauer M, Heavens R, Rigby M et al. Induction of c-fos mRNA in the arcuate nucleus of normal and mutant growth hormone-deficient mice by a synthetic non-peptidyl growth hormone secretagogue. Molecular Neuroscience 1995 6 1989-1992.
66. Ishii S, Okada K, Suzuki N, Sugihara H, Minami S, Shibasaki T & Wakabayashi I. Effect of growth hormone-releasing peptide (KP-102) on food intake in rats. 10th International Congress of Endocrinology. San Francisco 1996, p 282 Abstract P1-589.
67. Frieboes RM, Murck H, Maier P, Schier T, Holsboer F & Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995 61 584-589.
68. Wu D, Chen C, Zhang J, Katoh K & Clark I. Effects in vitro of new growth hormone releasing peptide (GHRP-1) on growth hormone secretion from ovine pituitary cells in primary culture. Journal of Neuroendocrinology 1994 6 185-190.
69. 2) in rat anterior pituitary cells. Endocrinology 1993 132 1286-1291.
70. Wu D, Chen C, Katoh K, Zhang J & Clarke J. The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist. Journal of Endocrinology 1994 140 9-13.
71. Chen K, Chan WWS, Butler B, Wei L, Schoen WR, Wyratt MJ et al. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology 1993 132 2729-2731.
72. Herrington J & Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms. Endocrinology 1994 135 1100-1108.
73. Locatelli V, Grilli R, Torsello A, Cella SG, Wehrenberg WB & Muller EE. Growth hormone-releasing hexapeptide is a potent stimulator of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat. Pediatric Research 1994 36 169-174.
74. Lindstrom P & Savendahl L. Effects of growth hormone (GH)-releasing hormone on GH release in isolated perifused rat type I and type II somatotrophs. Journal of Neuroendocrinology 1994 60 (Suppl 1) 3 (Abstract).
75. 2 in the rat. Endocrinology 1985 117 1441-1447.
76. Walker RF, Yang SW & Bercu BB. Robust growth hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sciences 1991 49 1499-1504.
77. Walker RF, Yang AW, Masuda R, Hu CS & Bercu BB. Effects of growth hormone releasing peptides on stimulated growth hormone secretion in old rats. In Growth Hormone II, Basic and Clinical Aspects pp 167-192. Eds BB Bercu & RF Walker. New York: Springer-Verlag, 1993.
78. Cella S, Locatelli V, Poratelli M, De Gennaro Colonna V, Imbimbo BP, Deghenghi R & Muller EE. Hexarelin, a potent GHRP analogue: interaction with GHRH and clonidine in young and aged dogs. Peptides 1995 16 81-86.
79. Fairhall KM, Mynett A & Robinson ICAF. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. Journal of Endocrinology 1995 144 555-560.
80. Fletcher TP, Thomas GB, Willoughby JO & Clarke IJ. Constitutive growth hormone secretion in sheep after hypothalamo-pituitary disconnection and the direct in vivo pituitary effect of growth hormone releasing peptide 6. Neuroendocrinology 1994 60 76-86.
81. Hickey GJ, Drisko J, Faidley T, Chang C, Anderson L, Nicolich S et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. Journal of Endocrinology 1996 148 371-380.
82. Hao EH, Malozowski S, Ren SG, Marin G, Southers J & Merriam G. A comparison of the effects of GH-releasing hormone (GHRH) and GH-releasing peptide (GHRP) on GH and somatostatin (SRIF) release. 70th Annual Meeting of the Endocrine Society. New Orleans 1988, Abstract 123.
83. Korbonits M, Little JA, Trainer PJ, Besser GM & Grossman AB. Analogues of growth hormone-releasing peptide (GHRP) do not affect the release of growth hormone-releasing hormone (GHRH) or somatostatin from the rat hypothalamus. Journal of Endocrinology 1996 148 (Suppl) 123.
84. 2 on GH release in conscious, freely moving male rats. Neuroendocrinology 1996 63 198-206.
85. Muller EE & Nistico G (Eds). Brain Messenger and the Pituitary. San Diego: Academic Press, 1989.
86. 2 in the dog. Journal of Endocrinology 1993 138 211-218.
87. Bercu BB, Yang SW, Masuda R & Walker RF. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone. Endocrinology 1992 130 2579-2586.
88. Dickson SL, Doutrelant-Viltart O & Leng G. GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6. Journal of Endocrinology 1995 146 519-526.
89. Chang CH, Faidley T, Rickes L, McGuire LA, Nicolich S, Murphy T, Frazier E, Chen H, Smith RG & Hickey J. Evidence that L-765,867 inhibits GH secretion when infused intravenously over a 12-hour period in swine. 10th International Congress of Endocrinology. San Francisco 1996, p 486 Abstract P2-328.
90. Tena-Sempere M, Pinilla L, Gonzalez D & Aguilar E. Nitric oxide (NO) blocked the GH response to growth hormone releasing hormone (GHRH), growth hormone releasing hexapeptide (GHRP-6). N-methyl-D-aspartate (NMDA) and kainic acid (KA). 10th International Congress of Endocrinology. San Francisco 1996. p 287 Abstract P1-612.
91. Torsello A, Locatelli V, Deghenghi R, Tolis G & Vrontakis ME. Galanin immunoneutralization inhibits Hexarelin stimulation of GH secretion in the rat. 77th Annual Meeting of the Endocrine Society, Washington, DC 1995, p 496 Abstract P3-110.
92. Bitar KG, Bowers CY & Coy DH. Effect of substance P/bombesin antagonists on the release of GH by GHRP and GHRH. Biochemical and Biophysical Research Communications 1991 5 156-161.
93. Bercu BB, Weideman CA & Walker RF. Sex differences in growth hormone (GH) secretion by rats administered GH-releasing hexapeptide. Endocrinology 1991 129 2592-2598.
94. Casanueva FF. Physiology of growth hormone secretion and action. In Endocrinology and Metabolism Clinics of North America pp 483-517. Ed S Melmed. Philadelphia: Saunders Company, 1992.
95. Fairhall KM, Mynett A, Smith RG & Robinson ICAF. Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585. Journal of Endocrinology 1995 145 417-426.
96. Dubreuil P, Petitclerc D, Pelletier G, Gaudeau P, Farmer C, Mowles TF et al. Effect of dose and frequency of administration of a potent analog of human growth hormone-releasing factor on hormone secretion in pigs. Journal of Animal Science 1990 68 1254-1268.
97. Thomas GB, Fairhall KM & Robinson ICAF. GH, ACTH and corticosterone responses to GHRP-6, CRF and AVP in conscious rats. 10th International Congress of Endocrinology. San Francisco 1996, p 282 Abstract P1-592.
98. Adams EF, Petersen B, Lei T, Hunchfelder M & Fanlbusch R. The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors. Biochemical and Biophysical Research Communications 1995 214 454-460.
99. Robinson ICAF. Mechanism of action of GHRPs in vivo. 10th International Congress of Endocrinology. San Francisco 1996, p 26 Abstract S10-2.
100. Scheim KD, Jacks T, Cunningham P, Feeney W, Frazier EG, Niebauer GW et al. Effect of MK-677 on growth hormone, IGF-I and cortisol in beagles before and after hypophysectomy. 10th International Congress of Endocrinology. San Francisco 1996, p 285 Abstract P1-603.
101. DeBell WK, Pezzoli SS & Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. Journal of Clinical Endocrinolosy and Metabolism 1991 72 1312-1316.
102. Imbimbo BP, Mant T, Edward M, Amin D, Froud A, Lenaerts U et al. Growth hormone releasing activity of Hexarelin in humans: a dose-response study. European Journal of Clinical Pharmacology 1994 46 421-425.
103. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. Journal of Clinical Endocrinology and Metabolism 1994 78 693-698.
104. Robinson BM, DeMott Friberg R, Bowers CY & Barkan AL. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans is independent of endogenous GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism 1992 75 1121-1124.
105. Gelato MC, Pescovitz DH, Cassorla F, Loriaux DL & Merriam GR. Dose-response relationships for the effects of GH-releasing factor 1-44 NH2 in young adult men and women. Journal of Clinical Endocrinology and Metabolism 1984 59 197-203.
106. Laron Z, Frenkel J, Gil-Ad I, Klinger B, Imbim E, Wuthrich P et al. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (Hexarelin). Clinical Endocrinology 1994 41 539-541.
107. Huhn WC, Hartman ML, Pezzoli SS & Thorner MO. Twentyfour-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. Journal of Clinical Endocrinology and Metabolism 1993 76 1202-1208.
108. Mazza E, Ghigo E, Goffi S, Procopio M, Imperiale E, Arvat E et al. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GHRH. Journal of Endocrinological Investigation 1989 12 795-798.
109. Vance ML, Borges JLC, Kaiser DL, Evans WS, Furlanetto R, Thominet JL et al. Human pancreatic tumor growth hormone-releasing factor (hp GRF-40): dose-response relationship in normal man. Journal of Clinical Endocrinology and Metabolism 1984 58 838-845.
110. Penalva A, Pombo M, Carballo A, Barreiro J. Casanueva FF & Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clinical Endocrinology 1993 38 87-91.
111. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM et al. Arginine enhances the growth hormone (GH)-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. Journal of Endocrinological Investigation 1994 17 157-162.
112. Ghigo E, Arvat E, Rizzi G, Goffi S, Mucci M, Boghen MF et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. European Journal of Endocrinology 1994 131 1-4.
113. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R et al. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of Hexarelin in elderly subjects. Journal of Clinical Endocrinology and Metabolism 1994 79 1440-1443.
114. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenaerts V et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, before and during puberty. Journal of Clinical Endocrinology and Metabolism 1995 80 1090-1094.
115. Micic D, Popovich V, Kendereski A, Macul D, Casanueva FE, Dieguez C & Laron Z. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clinical Endocrinology 1995 42 191-194.
116. Ghigo E, Arvat E, Goffi S, Bellone J, Nicolosi M, Procopio M et al. Neural control of growth hormone secretion in aged humans. In Growth Hormone and Somatomedins During Lifespan, pp 275-287. Eds EE Muller, D Cocchi, V Locatelli. Berlin: Springer-Verlag, 1993.
117. Chatelain P, Claris O, Lapillome A, Dimayo M & Salle B. Fetal and neonatal somatotroph function. Frontiers in Paediatric Neuroendocrinology 1994 20 127-130.
118. Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P et al. The growth hormone-releasing activity of Hexarelin, a new synthethic hexapeptide, in short normal and obese children and in hypopituitary subjects. Journal of Clinical Endocrinology and Metabolism 1995 80 674-678.
119. Arvat E, Gianotti L, Broglio F, Maccagno B, Bertagna A, Deghenghi R et al. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in postmenopausal women. European Journal of Endocrinology 1997 (In Press).
120. Ghigo E. Neurotransmitter control of growth hormone secretion. In Growth Hormone and Somatic Growth, pp 103-136. Ed LF de la Cruz. Amsterdam: Excerpta Medica, 1992.
121. Arvat E, Ceda GP, Ramunni J, DiVito L, Gianotti L, Boghen MF et al. Supramaximal doses of GHRH or Hexarelin, a synthetic hexapeptide, enhance the low somatotrope responsiveness in aging. Journal of Endocrinological Investigation 1996 19 (Suppl 5) 3.
122. Korbonits M, Trainer PJ & Besser GM. The effect of an opiate antagonist on the hormonal changes induced by Hexarelin. Clinical Endocrinology 1995 43 365-371.
123. Bowers CY. Novel GH-releasing peptides. In Molecular and Clinical Advances in Pituitary Disorders, p 153. Los Angeles: Endocrine Research Education Inc., 1993.
124. Giustina A, Bussi AR, Deghenghi R, Imbimbo BP, Licini M, Poiesi C et al. Comparison of the effects of growth hormone-releasing hormone and Hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. Journal of Endocrinology 1995 146 227-232.
125. Massoud AF, Hindmarsh PC, Matthews DR & Brook CGD. The effect of repeated administration of Hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Clinical Endocrinology 1996 44 555-562.
126. Arvat E, Gianotti L, Ramunni J, Di Vito L, Deghenghi R, Camanni F & Ghigo E. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. Journal of Endocrinological Investigation 1996 19 25-29.
127. Cordido F, Penalva A, Peino R, Casanueva FF & Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995 44 745-748.
128. Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R et al. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of Hexarelin in man. Metabolism 1997 46 83-88.
129. Gertz BJ, Sciberras DG, Yogendran L, Christie K, Bador K, Krupa D et al. L-692,429, a non-peptide growth hormone (GH) secretagogue reverses glucocorticoid suppression of GH secretion. Journal of Clinical Endocrinology and Metabolism 1994 79 745-749.
130. Massoud AF, Hindmarsh PC & Brook CGU. Hexarelin-induced growth hormone release is influenced by exogenous growth hormone. Clinical Endocrinology 1995 43 617-621.
131. Cappa M, Setzu S, Bernardini S, Carta D, Federici G, Grossi A et al. Exogenous growth hormone administration does not inhibit the growth hormone response to Hexarelin in normal men. Journal of Endocrinological Investigation 1995 18 762-766.
132. Peino R, Cordido F, Penalva A, Alvarez V, Dieguez C & Casanueva FF. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli. Journal of Clinical Endocrinology and Metabolism 1996 81 909-913.
133. Loche S, Cambiaso P, Merola B, Colao A, Faedda A, Imbimbo BP et al. The effect of Hexarelin on growth hormone (GH) secretion in patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism 1995 80 2692-2696.
134. Pombo M, Harreiro J, Penalva A, Peino R, Dieguez C & Casanueva FF. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. Journal of Clinical Endocrinology and Metabolism 1995 80 3180-3184.
135. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY & Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. Journal of Clinical Endocrinology and Metabolism 1993 77 1641-1647.
136. Thorner MO, Vance ML, Rogol AD, Blizzard RM, Veldhuis JD, Van Cauter E et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as potential therapeutic modalities. Acta Paediatrica Scandinavica 1990 367 (Suppl) 29-32.
137. Sartorio A, Conti A, Ferrero S, Spada A & Faglia G. GH responsiveness to repeated GHRH or Hexarelin administration in normal adults. Journal of Endocrinological Investigation 1995 18 718-722.
138. Ghigo E, Arvat E, Gianotti L, Grottoli S. Rizzi G, Ceda GP et al. Short term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the GH responsiveness in human aging. European Journal of Endocrinology 1996 135 790-795.
139. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B & Silbergeld A. Intranasal administration of the GHRP Hexarelin accelerates growth in short children. Clinical Endocrinology 1995 43 631-635.
140. Van der Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F et al. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotropin-releasing hormone in critical illness. Clinical Endocrinology 1996 45 341-351.
141. Laron Z, Bowers CY, Hirsch D, Almonte AS, Pelz N, Keret R et al. Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents. Acta Endocrinologica 1993 129 424-426.
142. Gianotti L, Arvat E, Ramunni J, Di Vito L, Maccagno B, Boghen MF et al. Effects of Hexarelin, a synthetic GH-releasing hexapeptide, in humans. Pharmacological Research 1995 31 (Suppl) 30.
143. Ghigo E. Effects of GHRPs during lifespan in humans. 10th International Congress of Endocrinology. San Francisco 1996, p 26 Abstract S10-4.
144. Renner U, Brockmeier S, Strasburger CJ, Lange M, Schopohl J, Muller OA et al. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide. Journal of Clinical Endocrinology and Metabolism 1994 78 1090-1096.
145. Lei T, Buchfelder M, Fahlbusch R & Adams EF. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. Journal of Molecular Endocrinology 1995 14 135-138.
146. 2). GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly. Journal of Clinical Endocrinology and Metabolism 1993 77 842-845.
147. Hanew K, Utsumi A, Sugawara A, Shimizu Y & Abe K. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1994 78 509-512.
148. Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C & Casanueva FF. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6. Journal of Clinical Endocrinology and Metabolism 1994 79 456-460.
149. Arosio M, Biella O, Casati G, Guglielmino L, Palmieri E & Faglia G. Effects of Hexarelin (EP23905-MF6003) on circulating GH levels in acromegalic patients. (Highlights in Molecular and Clinical Endocrinology). Frontiers in Endocrinology 1994 9 151-154.
150. Ciccarelli E, Grottoli S, Razzore P, Gianotti L, Arvat E, Deghenghi R et al. Hexarelin, a synthetic growth hormone-releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Clinical Endocrinology 1996 44 67-71.
151. 1) insensitive to GH-releasing hormone. 10th International Congress of Endocrinology. San Francisco 1996, p 288 Abstract P1-615.
152. Popovic V, Micic D, Damjanovic S, Djurovic M, Simic M, Gligorovic M & Dieguez C. Evaluation of pituitary GH reserve with GHRP-6. Journal of Pediatric Endocrinology and Metabolism 1996 9 289-298.
153. Ramos-Dias JC, Pimentel Filho F, Reis AF & Lengyel AMJ. Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1996 81 1343-1346.
154. Rolla M, Andreoni A, Bellitti D, Cristofani R, Ferdeghini M & Muller EE. Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. Biological Psychiatry 1991 29 1079-1091.
155. Valcavi R, Dieguez C, Zini M, Muruais C, Casanueva F & Portioli I. Influence of hyperthyroidism on growth hormone secretion. Clinical Endocrinology 1993 38 515-522.
156. Pihoker C, Middleton R, Reynolds GA, Bowers CY & Badger TM. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. Journal of Clinical Endocrinology and Metabolism 1995 80 2987-2992.
157. Bellone J, Ghizzoni L, Aimaretti G, Volta C, Boghen MF, Bernasconi S et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. European Journal of Endocrinology 1995 133 425-429.
158. Tuilpakov AN, Bulatov AA, Peterkova A, Elizarova GP, Volevodz NN & Bowers CY. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism 1995 44 1199-1204.
159. Mericq V, Cassorla F, Garcia H, Avila A, Bowers CY & Merriam GR. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. Journal of Clinical Endocrinology and Metabolism 1995 80 1681-1684.
160. Leal-Cerro A, Garcia E, Astorga R, Casanueva FF & Dieguez C. Growth hormone (GH) responses to the combined administration of GH-releasing peptide 6 in adults with GH deficiency. European Journal of Endocrinology 1995 132 712-715.
161. Pombo M, Barreiro J, Penalva A, Mallo F, Casanueva FF & Dieguez C. Plasma growth hormone response to growth hormone releasing hexapeptide (GHRP-6) in children with short stature. Acta Paediatrica 1995 84 904-908.
162. Chapman IM, Pescovitz OH, Treep T, Murphy G, Cerchio K, Krupa D, Gertz B, Polvino W, Skiles EH, Pezzoli SS & Thorner MO. Oral administration of the GHRP-mimetic MK-0677 stimulates the GH/IGF-I axis in GH deficient adults. 10th International Congress of Endocrinology. San Francisco 1996. p 769 Abstract P3-58.
163. Thorner MO, Hartman ML & Gaylinn BD. Current status of therapy with growth hormone-releasing neuropeptides. In Frontiers in Paediatric Neuroendocrinology, pp 161-167. Eds MO Savage, J Bourgulgon & AB Grossman. Oxford: Blackwell Scientific, 1994.
164. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY et al. Increased growth velocity during prolonged GHRP-2 administration to growth hormone deficient children. 77th Annual Meeting of the Endocrine Society. Washington 1995, p 85 Abstract OR 30-3.
165. Klinger B, Silbergeld A, Deghenghi R, Frenkel J & Laron Z. Desensitization from long-term intranasal treatment with Hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. European Journal of Endocrinology 1996 134 716-719.
166. Pihoker C, Badger TM, Reynolds GA & Bowers CY. Intranasal growth hormone (GH) releasing peptide-2 (GHRP-2) in children with GH deficiency: growth effects and GH secretion: studies during treatment. 10th International Congress of Endocrinology. San Francisco 1996, p 768 Abstract P3-54.
167. Cordido F, Penalva A, Dieguez C & Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. Journal of Clinical Endocrinology and Metabolism 1993 76 819-823.
168. Cordido F, Peino R, Penalva A, Alvarez CV, Casanueva FF & Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. Journal of Clinical Endocrinology and Metabolism 1996 81 914-918.
169. Grottoli S, Maccario M, Procopio M, Oleandri S, Razzore P, Talliano M et al. Selective refractoriness of somatotrope secretion to the inhibitory effect of hyperglycemia in obesity. European Journal of Endocrinology 1996 135 678-682.
170. 2. Journal of Endocrinology 1989 121 31-36.
171. Casanueva FF. GHRP-6 in disease states associated with impaired growth hormone secretion. International Symposium on Growth Hormone Secretagogues. St Petersburg Beach, Florida 1994, Abstract 22.
172. Leal Cerro A, Pumar A, Garcia-Garcia E, Dieguez C & Casanueva FF. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clinical Endocrinology 1994 41 649-654.
173. Dieguez C, Mallo F, Senaris R, Pineda J, Martul P, Leal-Cerro A, Pombo M & Casanueva FF. Role of glucocorticoids in the neuroregulation of growth hormone secretion. Journal of Pediatrics Endocrinology and Metabolism 1996 9 255-260.
174. Ghigo E, Bellone J, Aimaretti G, Bellone S, Loche S, Cappa M et al. Reliability of provocative tests to assess GH secretory status. Study in 472 normally growing children. Journal of Clinical Endocrinology and Metabolism 1996 81 3323-3327.
175. Spiliotis BE, August GP, Hung W, Sonis W, Mendelson W & Bercu B. Growth hormone neurosecretory dysfunction. A treatable cause of short stature. Journal of the American Medical Association 1984 251 2223.
176. Zadik Z, Chalew SA, Raiti S & Kowarsky AA. Do short children secrete insufficient growth hormone? Pediatrics 1985 76 355-360.
177. Thorner MO, Bengtsson BA, Ho KKY, Albertsson-Wikland K, Christiansen JS, Faglia G et al. Diagnosis of growth hormone deficiency in adults. Journal of Clinical Endocrinology and Metabolism 1995 80 3097-3098.
178. De Boer H, Blok G & Van Der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86.
179. Guida H. Final height attainment in normal children with short stature treated with growth hormone. Pediatric Research 1993 33 (Suppl 5) 10.
180. Rudman D, Feller AG & Nagraj HS. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine 1990 323 1-6.
181. Corpas E, Harman SM & Blackman G. Human growth hormone and human aging. Endocrine Reviews 1993 14 20-39.
182. Ross JRJM & Chew SL. Acquired growth hormone resistance. European Journal of Endocrinology 1995 132 655-660.
183. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordamo A, Guida R et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. New England Journal of Medicine 1996 334 100-103.